A Case of Pituitary Macroadenoma Concurrently Diagnosed in a Patient Undergoing Antipsychotic Treatment.
- Author:
Bong Sun KIM
1
;
Joo Sung KIM
;
Hyong Kyu RYU
;
Jin Woong PARK
;
Sun A HYUN
;
Je Wook KANG
;
Yong Jun CHOI
Author Information
- Publication Type:Case Report
- Keywords: Prolactinoma; Bromocriptine; Antipsychotic agents
- MeSH: Antipsychotic Agents; Bromocriptine; Dopamine; Dopamine Agonists; Humans; Hyperprolactinemia; Pituitary Gland; Pituitary Neoplasms; Prolactinoma; Psychotic Disorders; Schizophrenia; Quetiapine Fumarate
- From:Korean Journal of Medicine 2015;88(1):78-82
- CountryRepublic of Korea
- Language:Korean
- Abstract: Antipsychotics are the drug of choice for patients with schizophrenia, but they can induce hyperprolactinemia and growth of pituitary adenomas by blocking dopamine 2 receptors in the pituitary gland. In contrast, the medical treatment for a prolactinoma is a dopamine agonist. Therefore, managing a patient concurrently diagnosed with a prolactinoma and psychosis is challenging. We describe a patient with schizophrenia who was diagnosed with a prolactinoma. We changed his neuroleptic to quetiapine and prescribed bromocriptine for the prolactinoma. As a result, the patient was successfully treated with a dopamine agonist and antipsychotic without psychotic exacerbation. Our case suggests that dopamine agonists can be administrated to patients with schizophrenia and a prolactinoma without adversely affecting their psychopathological status.
